



**ASX Release**

---

**APPOINTMENT OF ANDREW GOODALL TO THE BOARD OF PRIME BIOLOGICS PTE LTD**

---

*Sydney, Thursday 10 Sept 2015*

NuSep Holdings Limited (ASX:**NSP, the Company** or **NuSep**) advises that Mr Andrew Goodall has been appointed to the board of PRIME Biologics Pte Ltd as NuSep's representative.

PRIME Biologics is a Singapore-based investment held by NuSep, focussed on applying the technology originally developed by NuSep to fractionate blood plasma.

Mr Goodall is a non-executive director of NuSep and a major shareholder of the Company. He replaces NuSep's Executive Chairman and NuSep's former representative on the board of PRIME Biologics Pte Ltd, Ms Alison Coutts.

**For further information please contact:**

Alison Coutts  
Executive Chairman  
+61 2 8415 7300  
alison.coutts@nusep.com